JMP Securities Upgrades Sarepta Therapeutic (SRPT) to Market Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Sarepta (SRPT) Wins Key PTO Decision on Composition of Matter Patents - Oppenheimer
September 20, 2016 1:18 PM EDTOppenheimer analyst Michelle Gilson notes US Patent and Trademark Office ruled in favor of Sarepta (NASDAQ: SRPT) for Patents 7,960,541 and 7,807,816 in its patent interference proceeding (interference number 106,008).
Gilson notes these cover composition of matter for eteplirsen, giving the Sarepta freedom to operate... More
Sarepta Therapeutic (SRPT) PT Raised to $66 at Wedbush
September 20, 2016 7:21 AM EDTWedbush analyst Heather Behanna reiterated an Outperform rating and boosted her price target on Sarepta Therapeutic (NASDAQ: SRPT) to $66.00 (from $36.00) after the FDA approved eteplirsen.
Behanna commented, "In line with our expectations after FDA asked for new data, eteplirsen has received accelerated... More
FDA Approves Sarepta Therapeutics' (SRPT) Eteplirsen
September 19, 2016 9:52 AM EDT(Updated - September 19, 2016 9:56 AM EDT)
The U.S. Food and Drug Administration today approved Sarepta Therapeutics' (Nasdaq: SRPT) Exondys 51 (eteplirsen) injection, the first drug approved to treat patients with Duchenne muscular dystrophy (DMD). Exondys 51 is specifically indicated for patients who have a confirmed mutation of the dystrophin gene amenable to exon 51 skipping, which affects about 13 percent of the population with DMD.
Patients with a particular type of Duchenne muscular dystrophy will now have access to an approved treatment for this rare and devastating disease, said Janet Woodcock, M.D., director of the... More
Sarepta Therapeutics (SRPT) Granted FDA Accelerated Approval for Eteplirsen
September 19, 2016 9:51 AM EDTSarepta Therapeutics (NASDAQ: SRPT) surges higher on FDA approval for eteplirsen
Letter from FDA
... More